Cargando…

Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma

Dendritic cells (DCs) are increasingly used as adjuvants for vaccination strategies; however, there has been very little development in DC vaccines for patients with hepatocellular carcinoma (HCC). In this study, we assessed the safety, feasibility and efficacy of a multiple tumor-associated antigen...

Descripción completa

Detalles Bibliográficos
Autores principales: TADA, FUJIMASA, ABE, MASANORI, HIROOKA, MASASHI, IKEDA, YOSHIOU, HIASA, YOICHI, LEE, YOON, JUNG, NAM-CHUL, LEE, WOO-BOK, LEE, HYUN-SOO, BAE, YONG-SOO, ONJI, MORIKAZU
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583872/
https://www.ncbi.nlm.nih.gov/pubmed/22971679
http://dx.doi.org/10.3892/ijo.2012.1626
_version_ 1782475496128249856
author TADA, FUJIMASA
ABE, MASANORI
HIROOKA, MASASHI
IKEDA, YOSHIOU
HIASA, YOICHI
LEE, YOON
JUNG, NAM-CHUL
LEE, WOO-BOK
LEE, HYUN-SOO
BAE, YONG-SOO
ONJI, MORIKAZU
author_facet TADA, FUJIMASA
ABE, MASANORI
HIROOKA, MASASHI
IKEDA, YOSHIOU
HIASA, YOICHI
LEE, YOON
JUNG, NAM-CHUL
LEE, WOO-BOK
LEE, HYUN-SOO
BAE, YONG-SOO
ONJI, MORIKAZU
author_sort TADA, FUJIMASA
collection PubMed
description Dendritic cells (DCs) are increasingly used as adjuvants for vaccination strategies; however, there has been very little development in DC vaccines for patients with hepatocellular carcinoma (HCC). In this study, we assessed the safety, feasibility and efficacy of a multiple tumor-associated antigen (TAA)-pulsed DC vaccine in 5 patients with advanced HCC. DCs were generated by culturing blood monocytes in the presence of granulocyte macrophage-colony stimulating factor and interleukin-4 for 5 days. The DC vaccine was prepared by pulsing DCs with cytoplasmic transduction peptide-attached α-fetoprotein, glypican-3 and MAGE-1 recombinant fusion proteins and cultivating them in the presence of maturation cocktail. DCs were injected subcutaneously near the inguinal lymph nodes, followed by topical application of toll-like receptor-7 agonist around the injection site. We showed that our DC vaccine was safe and well-tolerated over 6 vaccinations in 5 patients. All 5 patients showed T cell responses against TAAs. Clinical benefit was observed in one of the 5 patients. In conclusion, the feasibility, safety and immune activity of DCs pulsed with TAAs were confirmed in HCC patients. However, clinical response was detected only in one patient. Future trials may consider applying this therapy in a less advanced stage to obtain better clinical responses.
format Online
Article
Text
id pubmed-3583872
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-35838722013-03-04 Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma TADA, FUJIMASA ABE, MASANORI HIROOKA, MASASHI IKEDA, YOSHIOU HIASA, YOICHI LEE, YOON JUNG, NAM-CHUL LEE, WOO-BOK LEE, HYUN-SOO BAE, YONG-SOO ONJI, MORIKAZU Int J Oncol Articles Dendritic cells (DCs) are increasingly used as adjuvants for vaccination strategies; however, there has been very little development in DC vaccines for patients with hepatocellular carcinoma (HCC). In this study, we assessed the safety, feasibility and efficacy of a multiple tumor-associated antigen (TAA)-pulsed DC vaccine in 5 patients with advanced HCC. DCs were generated by culturing blood monocytes in the presence of granulocyte macrophage-colony stimulating factor and interleukin-4 for 5 days. The DC vaccine was prepared by pulsing DCs with cytoplasmic transduction peptide-attached α-fetoprotein, glypican-3 and MAGE-1 recombinant fusion proteins and cultivating them in the presence of maturation cocktail. DCs were injected subcutaneously near the inguinal lymph nodes, followed by topical application of toll-like receptor-7 agonist around the injection site. We showed that our DC vaccine was safe and well-tolerated over 6 vaccinations in 5 patients. All 5 patients showed T cell responses against TAAs. Clinical benefit was observed in one of the 5 patients. In conclusion, the feasibility, safety and immune activity of DCs pulsed with TAAs were confirmed in HCC patients. However, clinical response was detected only in one patient. Future trials may consider applying this therapy in a less advanced stage to obtain better clinical responses. D.A. Spandidos 2012-09-11 /pmc/articles/PMC3583872/ /pubmed/22971679 http://dx.doi.org/10.3892/ijo.2012.1626 Text en Copyright © 2012, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Articles
TADA, FUJIMASA
ABE, MASANORI
HIROOKA, MASASHI
IKEDA, YOSHIOU
HIASA, YOICHI
LEE, YOON
JUNG, NAM-CHUL
LEE, WOO-BOK
LEE, HYUN-SOO
BAE, YONG-SOO
ONJI, MORIKAZU
Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma
title Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma
title_full Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma
title_fullStr Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma
title_full_unstemmed Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma
title_short Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma
title_sort phase i/ii study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583872/
https://www.ncbi.nlm.nih.gov/pubmed/22971679
http://dx.doi.org/10.3892/ijo.2012.1626
work_keys_str_mv AT tadafujimasa phaseiiistudyofimmunotherapyusingtumorantigenpulseddendriticcellsinpatientswithhepatocellularcarcinoma
AT abemasanori phaseiiistudyofimmunotherapyusingtumorantigenpulseddendriticcellsinpatientswithhepatocellularcarcinoma
AT hirookamasashi phaseiiistudyofimmunotherapyusingtumorantigenpulseddendriticcellsinpatientswithhepatocellularcarcinoma
AT ikedayoshiou phaseiiistudyofimmunotherapyusingtumorantigenpulseddendriticcellsinpatientswithhepatocellularcarcinoma
AT hiasayoichi phaseiiistudyofimmunotherapyusingtumorantigenpulseddendriticcellsinpatientswithhepatocellularcarcinoma
AT leeyoon phaseiiistudyofimmunotherapyusingtumorantigenpulseddendriticcellsinpatientswithhepatocellularcarcinoma
AT jungnamchul phaseiiistudyofimmunotherapyusingtumorantigenpulseddendriticcellsinpatientswithhepatocellularcarcinoma
AT leewoobok phaseiiistudyofimmunotherapyusingtumorantigenpulseddendriticcellsinpatientswithhepatocellularcarcinoma
AT leehyunsoo phaseiiistudyofimmunotherapyusingtumorantigenpulseddendriticcellsinpatientswithhepatocellularcarcinoma
AT baeyongsoo phaseiiistudyofimmunotherapyusingtumorantigenpulseddendriticcellsinpatientswithhepatocellularcarcinoma
AT onjimorikazu phaseiiistudyofimmunotherapyusingtumorantigenpulseddendriticcellsinpatientswithhepatocellularcarcinoma